Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to HIV virological suppression
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control. This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma-related mortality at 1 year and overall survival at 5 years. METHODS: We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV-1 RNA <100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis. RESULTS: [IQR 202-583], p < 0.001) and more advanced Ann Arbor stage (stage III-IV: 82.0% vs. 64.1%, p = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%, p = 0.779). Furthermore, virological suppression was not independently associated with 1-year lymphoma-specific or 5-year overall survival. CONCLUSIONS: In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.
Source: HIV Medicine
DOI: 10.1111/hiv.70257
Authors: Teresa Aldámiz‐Echevarria, Francisco Tejerina, Chiara Fanciulli, Cristina Diez, Leire Perez, José Maria Bellón, Nuria Espinosa, Santiago Moreno Guillén, Maria del Mar Arcos‐Rueda, Marta Montero‐Alonso, Lucio García‐Fraile, Victor Asensi, Marian Fernández López, Diana Corona‐Mata, Alfonso Cabello‐Úbeda, Meritxell Gavaldà Manso, Jose Antonio Iribarren, Laura Pérez‐Martínez, María Remedios Alemán Valls, Irene Portilla‐Tamarit, Joaquim Peraire, Inés Suárez‐García, Mar Masiá, María José Núñez Orantos, Ángela Gutiérrez Liarte, Arkaitz Imaz, Cristina Hernández Gutiérrez, Maria Tasias Pitarch, Marta Rava, CoRIS Cohort
Institutions: Instituto de Salud Carlos III, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Universitario Virgen del Rocío, Universidad de Alcalá, Hospital Universitario Ramón y Cajal, Hospital Universitario La Paz, Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe, Hospital Universitario de La Princesa, Universidad de Oviedo, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Hospital Universitario Virgen de la Arrixaca, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, University of Córdoba, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Hospital Universitario Son Espases, University of the Basque Country, Donostiako Unibertsitate Ospitalea, Center for Biomedical Research of La Rioja, Servicio Riojano de Salud, Hospital Universitario de Canarias, University of Alicante, Hospital General Universitario de Alicante Doctor Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Institut de Recerca Biomèdica Catalunya Sud, Hospital Universitari Joan XXIII de Tarragona, Universitat Rovira i Virgili, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, Universitat de Miguel Hernández d'Elx, Hospital General Universitario de Elche, Hospital Clínico San Carlos, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Universitat de Barcelona, Hospital Universitario Príncipe de Asturias, Universitat de València
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,150
Funder: Instituto de Salud Carlos III
OpenAlex ID: W7161564229